May 19, 2016
Ibrutinib and ABT199 for CLLVideo Categories: ASH 2014
August 29, 2018
How PD-L1 Biomarker Test Results Impact Clinical Management of Lung Cancer
Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.
January 30, 2014
Selecting the Appropriate Test for Individual Patients and Tumors
In this next segment, Dr Agarwala discusses when and how molecular tests should be utilized.